Main Session 6: Proliferative Diabetic Retinopathy in 2018: Pragmatic Application of Evidence Based Medicine

Chairpersons: A. Laidlaw UK, E. Midena ITALY, M. Goldstein ISRAEL

 

M. Larsen DENMARK                                                                                                                                             Pathophysiology, classification, Threshold for laser  

E. Pilotto ITALY                                                                                                                                                                                    Retinal photocoagulation: pros and cons

Anti-VEGF and proliferative diabetic retinopathy trial data:
i. Clarity: S. Sivaprasad UK 
ii. Protocol S: J. Wells USA

R. Schlingemann THE NETHERLANDS 
How might Protocol S and Clarity results be generalised in current practice?

N. Bressler USA 
Cost effectiveness of anti-VEGF therapy for PDR

D. Steel UK 
Vitrectomy in PDR 2018

Chaired panel discussion – pragmatic evidence based management of PDR in 2018
Specific scenarios:
– Severe NPDR, treat don’t treat
– Low risk NVD/E treat don’t treat: with what?
– HRC: no macular edema
– HRC: with macular edema
– Persistent NV after standard PRP
– Mild vitreous haemorrhage after full PRP
– Florid PDR no previous treatment

End of session

 

Back

Want to find out more about EURETINA activities?

Contact us
© EURETINA All rights reserved